On June 2, 2025, Escugen presented the latest data from the Phase I clinical trial of ESG401 (Trop2 ADC) in advanced solid tumors at the 2025 ASCO meeting in the form of a poster.

From May 30 to June 3, 2025, the largest and most prestigious global oncology conference—the American Society of Clinical Oncology (ASCO) Annual Meeting—will be held at the McCormick Place Convention Center in Chicago, USA. Escugen’s TROP2 ADC product ESG401 will present two research findings at this year’s conference. This marks the third consecutive year that the clinical progress of ESG401 has been selected for presentation at the ASCO Annual Meeting.